Marshall Edwards Appoints CEO as a New Director
06 mai 2010 08h00 HE
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - May 6, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer...
Nine Educational Models Studied by Over 160 Veterinary Medical Education Stakeholders at Second NAVMEC National Meeting
03 mai 2010 09h00 HE
|
NAVMEC
KANSAS CITY, MO--(Marketwire - May 3, 2010) - A diverse representation of veterinary organizations and individuals ever assembled completed three days of meetings Saturday to examine current...
Marshall Edwards, Inc. Announces Grants Under Nasdaq Rule 5635
29 avr. 2010 08h00 HE
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - April 29, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHLD), a specialist oncology company focusing on the clinical development of novel anti-cancer...
Marshall Edwards Appoints New President and CEO
26 avr. 2010 08h00 HE
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - April 26, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHLD), an oncology company focused on the clinical development of novel anti-cancer therapeutics,...
Marshall Edwards, Inc. Receives Notice of Compliance With Nasdaq Continued Listing Requirements
20 avr. 2010 09h00 HE
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - April 20, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), a specialist oncology company focusing on the clinical development of novel anti-cancer therapeutics, today...
Novogen Announces New Executive Service Agreements
31 mars 2010 08h00 HE
|
Novogen Limited
SYDNEY, AUSTRALIA--(Marketwire - March 31, 2010) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN) advises that it has entered into new executive service agreements with its seven most senior executives.
...
Marshall Edwards, Inc. Announces Stockholder Approval and Implementation of 1:10 Reverse Stock Split
31 mars 2010 08h00 HE
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - March 31, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL) (NASDAQ: MSHLD), a specialist oncology company focusing on the clinical development of novel anti-cancer...
HemoBioTech and Its Innovative Blood Substitute HemoTech Could Benefit From House Resolution to Support Small Biotechnology Companies
25 mars 2010 08h00 HE
|
HemoBioTech
DALLAS, TX--(Marketwire - March 25, 2010) - Congressman Danny K. Davis (Il-7th) recently submitted House Resolution 1179, legislation that puts Congress on record in supporting biotechnology...
Marshall Edwards, Inc. Receives Nasdaq Staff Determination
19 mars 2010 08h00 HE
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - March 19, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), a specialist oncology company focusing on the clinical development of novel anti-cancer therapeutics,...
New Path to Therapeutic HIV Vaccine Discovered by Studying Immunologic Profile of Rare HIV Controllers
17 mars 2010 11h30 HE
|
Bionor Immuno
OSLO, NORWAY--(Marketwire - March 17, 2010) - Based on encouraging results from pre-clinical research, Bionor Immuno AS today announced intentions to take the therapeutic and potentially...